[
  {
    "ts": null,
    "headline": "RQM+ Appoints Ross D. Segan, MD, MBA, FACS, to Board of Directors",
    "summary": "PITTSBURGH, January 08, 2026--RQM+, a leading global MedTech service provider (CRO), today announced that Ross D. Segan, M.D., MBA, FACS, has joined its board of directors. Dr. Segan is a physician–executive and MedTech strategist with senior leadership experience at the U.S. Food and Drug Administration (FDA), Johnson & Johnson, Olympus, Covidien, and Vensana Capital, and currently serves as CEO of Medical Scientific Advisors, LLC.",
    "url": "https://finnhub.io/api/news?id=dde36fa0d1f79fe648f25312c82d787150e1117d05307df8cf3de88f4cc9567f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767880800,
      "headline": "RQM+ Appoints Ross D. Segan, MD, MBA, FACS, to Board of Directors",
      "id": 138036604,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "PITTSBURGH, January 08, 2026--RQM+, a leading global MedTech service provider (CRO), today announced that Ross D. Segan, M.D., MBA, FACS, has joined its board of directors. Dr. Segan is a physician–executive and MedTech strategist with senior leadership experience at the U.S. Food and Drug Administration (FDA), Johnson & Johnson, Olympus, Covidien, and Vensana Capital, and currently serves as CEO of Medical Scientific Advisors, LLC.",
      "url": "https://finnhub.io/api/news?id=dde36fa0d1f79fe648f25312c82d787150e1117d05307df8cf3de88f4cc9567f"
    }
  },
  {
    "ts": null,
    "headline": "J&J's Innovative Medicine Segment in Q4: Here's What to Watch",
    "summary": "JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds.",
    "url": "https://finnhub.io/api/news?id=6504141003373658159135795e727406f16b5d90be00443478ca477255688173",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767880620,
      "headline": "J&J's Innovative Medicine Segment in Q4: Here's What to Watch",
      "id": 138036605,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds.",
      "url": "https://finnhub.io/api/news?id=6504141003373658159135795e727406f16b5d90be00443478ca477255688173"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson celebrates innovation in cancer research with 2025 Dr. Paul Janssen Award",
    "summary": "Johnson & Johnson today announced Tony Hunter, Ph.D., of the Salk Institute as the recipient of the 2025 Dr. Paul Janssen Award for Biomedical Research. Dr. Hunter is honored for his role in the discovery of tyrosine kinases and protein-tyrosine phosphorylation as mechanisms for the malignant transformation of normal cells into cancer cells and other disease states.",
    "url": "https://finnhub.io/api/news?id=e8c38354add2a68c02d0dc29901b1a22263e3abbf510817adcb6e2226a2f613c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767877200,
      "headline": "Johnson & Johnson celebrates innovation in cancer research with 2025 Dr. Paul Janssen Award",
      "id": 138036606,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson today announced Tony Hunter, Ph.D., of the Salk Institute as the recipient of the 2025 Dr. Paul Janssen Award for Biomedical Research. Dr. Hunter is honored for his role in the discovery of tyrosine kinases and protein-tyrosine phosphorylation as mechanisms for the malignant transformation of normal cells into cancer cells and other disease states.",
      "url": "https://finnhub.io/api/news?id=e8c38354add2a68c02d0dc29901b1a22263e3abbf510817adcb6e2226a2f613c"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Johnson & Johnson: “I Think It’s a Terrific Entry Point”",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer offered insights on. Cramer highlighted the company’s latest spin-off plans for one of its divisions, as he commented: “The fastest grower, the best opportunity here would not be Eli Lilly, which has moved a great deal and I still like, but Johnson & Johnson. […]",
    "url": "https://finnhub.io/api/news?id=bba4de0690500d2b1c69720b1269471493564386b4cfb4c10b8abffc454c4e8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767876310,
      "headline": "Jim Cramer on Johnson & Johnson: “I Think It’s a Terrific Entry Point”",
      "id": 138036593,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer offered insights on. Cramer highlighted the company’s latest spin-off plans for one of its divisions, as he commented: “The fastest grower, the best opportunity here would not be Eli Lilly, which has moved a great deal and I still like, but Johnson & Johnson. […]",
      "url": "https://finnhub.io/api/news?id=bba4de0690500d2b1c69720b1269471493564386b4cfb4c10b8abffc454c4e8c"
    }
  },
  {
    "ts": null,
    "headline": "Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy",
    "summary": "Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson’s expertise in cardiovascular therapeutics and circulatory technologies, including Impella™ heart pumps Agreement will enable accelerated development of a preclinical cardiac target using novel, localized routes of viral gene therapy administration NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel",
    "url": "https://finnhub.io/api/news?id=1b678132d043193a8cf969ca854f0ce153be0e7bd935041e5e039e3104a57c61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767873600,
      "headline": "Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy",
      "id": 138034988,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson’s expertise in cardiovascular therapeutics and circulatory technologies, including Impella™ heart pumps Agreement will enable accelerated development of a preclinical cardiac target using novel, localized routes of viral gene therapy administration NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel",
      "url": "https://finnhub.io/api/news?id=1b678132d043193a8cf969ca854f0ce153be0e7bd935041e5e039e3104a57c61"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Kenvue (KVUE) After Share Price Slide And Johnson & Johnson Separation",
    "summary": "If you are wondering whether Kenvue's current share price reflects fair value or a potential opportunity, you are in the right place. The stock closed at US$16.74 with returns of a 3.0% decline over 7 days, a 0.1% decline over 30 days, a 3.3% decline year to date and a 17.4% decline over the last year, which may have shifted how investors think about its risk and return trade off. Recent coverage around Kenvue has focused on its position as a stand alone consumer health company following its...",
    "url": "https://finnhub.io/api/news?id=8c1261a84ec42904081ecb3494b2265cdb2f062a8d459842b8fe92b1d40f464e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767870441,
      "headline": "Assessing Kenvue (KVUE) After Share Price Slide And Johnson & Johnson Separation",
      "id": 138034989,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "If you are wondering whether Kenvue's current share price reflects fair value or a potential opportunity, you are in the right place. The stock closed at US$16.74 with returns of a 3.0% decline over 7 days, a 0.1% decline over 30 days, a 3.3% decline year to date and a 17.4% decline over the last year, which may have shifted how investors think about its risk and return trade off. Recent coverage around Kenvue has focused on its position as a stand alone consumer health company following its...",
      "url": "https://finnhub.io/api/news?id=8c1261a84ec42904081ecb3494b2265cdb2f062a8d459842b8fe92b1d40f464e"
    }
  },
  {
    "ts": null,
    "headline": "EpiBiologics Closes $107M Series B to Advance Pipeline of Novel Bispecific Antibodies to Selectively Degrade Extracellular Protein Targets in Oncology and Immunology",
    "summary": "SAN MATEO, Calif., January 08, 2026--EpiBiologics, a leader in tissue-selective extracellular protein degradation, today announced the completion of a $107 million Series B financing co-led by GV (Google Ventures) and Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc (JJDC).",
    "url": "https://finnhub.io/api/news?id=c8b80254f1573f90816edca905d2fc6cb86684ae01aed4512044ebe568804c3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767870000,
      "headline": "EpiBiologics Closes $107M Series B to Advance Pipeline of Novel Bispecific Antibodies to Selectively Degrade Extracellular Protein Targets in Oncology and Immunology",
      "id": 138034990,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "SAN MATEO, Calif., January 08, 2026--EpiBiologics, a leader in tissue-selective extracellular protein degradation, today announced the completion of a $107 million Series B financing co-led by GV (Google Ventures) and Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc (JJDC).",
      "url": "https://finnhub.io/api/news?id=c8b80254f1573f90816edca905d2fc6cb86684ae01aed4512044ebe568804c3c"
    }
  },
  {
    "ts": null,
    "headline": "Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics",
    "summary": "Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today announced the appointment of Lawrence M. Blatt, PhD, MBA as Chair of its Board of Directors. Dr. Blatt brings substantial expertise in strategic leadership, drug development and operations together with extensive experience, to guide and support Onco3R’s portfolio development and its next stage of growth. He",
    "url": "https://finnhub.io/api/news?id=14ddbf63aa5b7fe80f523b8fa3cbf2f6cf0f2274a99f2c15cb055f95c76ed643",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767859200,
      "headline": "Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics",
      "id": 138033052,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with best-in-class medicines, today announced the appointment of Lawrence M. Blatt, PhD, MBA as Chair of its Board of Directors. Dr. Blatt brings substantial expertise in strategic leadership, drug development and operations together with extensive experience, to guide and support Onco3R’s portfolio development and its next stage of growth. He",
      "url": "https://finnhub.io/api/news?id=14ddbf63aa5b7fe80f523b8fa3cbf2f6cf0f2274a99f2c15cb055f95c76ed643"
    }
  },
  {
    "ts": null,
    "headline": "Should J&J’s Nipocalimab SLE Win and OTTAVA Robot Push Require Action From Johnson & Johnson (JNJ) Investors?",
    "summary": "In early January 2026, Johnson & Johnson reported that nipocalimab (Imaavy) met primary and key secondary endpoints in the Phase 2b JASMINE trial for systemic lupus erythematosus and moved the program into Phase 3, while also advancing its MedTech ambitions with an FDA De Novo submission for the OTTAVA robotic surgical system in general surgery. This combination of a potentially first-in-class FcRn blocker in SLE and a next-generation soft-tissue surgery robot underscores Johnson &...",
    "url": "https://finnhub.io/api/news?id=7fa340ded48fdf8b419b9263c94a989d686a19a9582f9444f1889b7e80a3f1b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767856436,
      "headline": "Should J&J’s Nipocalimab SLE Win and OTTAVA Robot Push Require Action From Johnson & Johnson (JNJ) Investors?",
      "id": 138033053,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "In early January 2026, Johnson & Johnson reported that nipocalimab (Imaavy) met primary and key secondary endpoints in the Phase 2b JASMINE trial for systemic lupus erythematosus and moved the program into Phase 3, while also advancing its MedTech ambitions with an FDA De Novo submission for the OTTAVA robotic surgical system in general surgery. This combination of a potentially first-in-class FcRn blocker in SLE and a next-generation soft-tissue surgery robot underscores Johnson &...",
      "url": "https://finnhub.io/api/news?id=7fa340ded48fdf8b419b9263c94a989d686a19a9582f9444f1889b7e80a3f1b1"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks In Focus: Assessing The Outlook For 2026",
    "summary": "After a prolonged slump, investors are giving the healthcare sector a second look. TD Asset Management's Jacky He discusses potential drivers for biotech and pharmaceutical stocks in 2026.",
    "url": "https://finnhub.io/api/news?id=3274ac6c8006bb91e5a1e993463154bbb35619d530559a7095996210d5b0fa19",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767850200,
      "headline": "Healthcare Stocks In Focus: Assessing The Outlook For 2026",
      "id": 138034430,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487494602/image_1487494602.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "After a prolonged slump, investors are giving the healthcare sector a second look. TD Asset Management's Jacky He discusses potential drivers for biotech and pharmaceutical stocks in 2026.",
      "url": "https://finnhub.io/api/news?id=3274ac6c8006bb91e5a1e993463154bbb35619d530559a7095996210d5b0fa19"
    }
  }
]